Article and Video CATEGORIES

Cancer Journey

Search By

 

Dr. Aakash Desai, MBBS, MPH serves as an Assistant Professor of Medicine at the O'Neal Cancer Center, University of Alabama Birmingham. His pioneering research is primarily concentrated in the realm of evidence-based oncology, clinical trials, drug development, healthcare delivery, and quality of cancer care. He holds a particular interest in Thoracic Oncology and drug development.

Click here for more information about Dr. Desai. 

 

Program: LCVL 2023
Oncologists discuss a variety of topics in lung cancer, including biomarker testing, immunotherapy, KRAS+ disease, and emerging therapies, among other topics.

Author
Aakash Desai, MD, MPH - Guest Faculty
Image
LCVL 2023

In this latest update to the Lung Cancer Video Library, Oncologists discuss a variety of topics in lung cancer including biomarker testing, immunotherapy, KRAS+, emerging therapies, the changes that have occurred in treating NSCLC in the past few decades, Lung Cancer risk factors, and treatment options.

To watch the full playlist click here.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on